GENE ONLINE|News &
Opinion
Blog

2023-06-07| Special

NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO’s Demo Day

by GeneOnline
Share To
NSTC organized Taiwan Smart Health Demo Day during 2023 US BIO, where 20 start-up companies showcased Taiwan's capabilities in biomedical innovation.

With the aim of supporting the international export of Taiwan’s biomedical industry and effectively attracting capital and attention from international companies, the National Science and Technology Council (NSTC) held the Taiwan Smart Health Demo Day at US BIO in Boston on June 6, with presentations by 20 biomedical start-ups and active participation by over 100 representatives from renowned venture capitalists, multinational pharmaceutical companies, public associations, and the BIO International Convention.

The event effectively assisted start-up teams in establishing global exposure and promoting cooperation and exchange between Taiwan’s biotech industry and the global market. Mr. Wu Tsung-tsong, Minister of Science and Technology, also visited the exhibition and Demo Day to cheer on Taiwanese teams and expressed his hope that they could showcase their innovative technologies through the exhibition and Demo Day, and successfully connect with overseas venture capitalists and major companies to gain global business opportunities.

The Demo Day was held in the form of Demo & Pitch, featuring presentations by 20 teams supported by NSTC. Among them, Taipei Veterans General Hospital, China Medical University Hospital and Show Chwan Memorial Hospital are the teams of NSTC’s Smart Healthcare Industry-Academia Consortium Project. Other teams came from the industry and universities with outstanding technologies and R&D achievements in the fields of biopharmaceuticals, small molecule drugs, CDMO, precision medicine, and smart medical devices. For example, the “Universal Antibody Lock Technology” developed by PrecisemAb can effectively reduce the side effects of antibodies and significantly improve the safety profile of drugs. JelloX Biotech has developed patented 3D pathology tissue processing and imaging technology to develop next-generation pathology detection technology. The innovative AI decision-making support system for immunotherapy developed by AESOP Technology navigates the precise combination of tumor type and cancer stage. Following the event, participating teams continued to exchange valuable insights with visitors through live demonstrations.

In addition, the US BIO Convention hosts the Start-Up Stadium, a unique contest for start-up teams from around the world to gain exposure at the world’s largest biotechnology partnering event. This year, more than 250 teams applied and only 48 made it to the finals, where three NSTC teams will compete against competitors worldwide for the championship. During the exhibition, NSTC led teams to establish connections with internationally renowned accelerators, such as SmartLabs, LabCentral and Harvard Life Lab. Looking ahead, NSTC will continue to create closer cooperation between Taiwan’s start-up companies and international investors through various exhibitions and business exchanges, thereby strengthening Taiwan’s start-up ecosystem.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Thai Biotech Industry’s Promising Potential: Taiwan Works Toward Strengthening APAC Ties at Bio Asia Pacific—Collaboration is Key
2024-09-24
International Green Party Showcases AI Solutions for a Healthy and Sustainable Future
2024-09-16
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
LATEST
Generative AI Makes its Debut in Smart Healthcare with NVIDIA Experts at the Helm
2024-10-04
TCELS’s Path to a Self-Sufficient Biotech Thailand: Entrepreneurs in Global Competitiveness, Raw Material Exports, and Cosmetic Innovations
2024-10-04
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
Eyes on Nvidia: A Strong Investment Prospect, Driving Billions in AI Development and Advanced Infrastructure
2024-09-30
Immunai and AstraZeneca’s $18 Million AI Collaboration to Transform Cancer Drug Development
2024-09-26
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
2024-10-28
BioFuture 2024
New York, U.S.A.
2024-10-30
AusBiotech 2024
Melbourne, Australia
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top